Erratum: Design and rationale of japanese evaluation between formula of azelnidipine and amlodipine add on olmesartan to get antialbuminuric effect study (J-FLAG) : Ion of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria (Cardiovascular Drugs and Therapy (2011) 25 (365366) DOI 10.1007/s10557-011-6309-5))

Katsuyuki Ando; Masakazu Haneda; Sadayoshi Ito; Naoki Kashihara; Koichi Node; Masaomi Nangaku; Tatsuo Shimosawa; Junji Kishimoto; Toshiro Fujita

doi:10.1007/s10557-011-6315-7

Erratum: Design and rationale of japanese evaluation between formula of azelnidipine and amlodipine add on olmesartan to get antialbuminuric effect study (J-FLAG) : Ion of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria (Cardiovascular Drugs and Therapy (2011) 25 (365366) DOI 10.1007/s10557-011-6309-5))

Katsuyuki Ando, Masakazu Haneda, Sadayoshi Ito, Naoki Kashihara, Koichi Node, Masaomi Nangaku, Tatsuo Shimosawa, Junji Kishimoto, Toshiro Fujita

ARO次世代医療センター

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

本文言語	英語
ページ（範囲）	365-366
ページ数	2
ジャーナル	Cardiovascular Drugs and Therapy
巻	25
号	4
DOI	https://doi.org/10.1007/s10557-011-6315-7
出版ステータス	出版済み - 8月 2011

!!!All Science Journal Classification (ASJC) codes

薬理学
循環器および心血管医学
薬理学（医学）

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1007/s10557-011-6315-7

他のファイルとリンク

引用スタイル

Ando, K., Haneda, M., Ito, S., Kashihara, N., Node, K., Nangaku, M., Shimosawa, T., Kishimoto, J., & Fujita, T. (2011). Erratum: Design and rationale of japanese evaluation between formula of azelnidipine and amlodipine add on olmesartan to get antialbuminuric effect study (J-FLAG) : Ion of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria (Cardiovascular Drugs and Therapy (2011) 25 (365366) DOI 10.1007/s10557-011-6309-5)). Cardiovascular Drugs and Therapy, 25(4), 365-366. https://doi.org/10.1007/s10557-011-6315-7

Erratum: Design and rationale of japanese evaluation between formula of azelnidipine and amlodipine add on olmesartan to get antialbuminuric effect study (J-FLAG) : Ion of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria (Cardiovascular Drugs and Therapy (2011) 25 (365366) DOI 10.1007/s10557-011-6309-5)). / Ando, Katsuyuki; Haneda, Masakazu; Ito, Sadayoshi その他.
In: Cardiovascular Drugs and Therapy, Vol. 25, No. 4, 08.2011, p. 365-366.

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

Ando, K, Haneda, M, Ito, S, Kashihara, N, Node, K, Nangaku, M, Shimosawa, T, Kishimoto, J & Fujita, T 2011, 'Erratum: Design and rationale of japanese evaluation between formula of azelnidipine and amlodipine add on olmesartan to get antialbuminuric effect study (J-FLAG) : Ion of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria (Cardiovascular Drugs and Therapy (2011) 25 (365366) DOI 10.1007/s10557-011-6309-5))', Cardiovascular Drugs and Therapy, vol. 25, no. 4, pp. 365-366. https://doi.org/10.1007/s10557-011-6315-7

Ando K, Haneda M, Ito S, Kashihara N, Node K, Nangaku M その他. Erratum: Design and rationale of japanese evaluation between formula of azelnidipine and amlodipine add on olmesartan to get antialbuminuric effect study (J-FLAG) : Ion of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria (Cardiovascular Drugs and Therapy (2011) 25 (365366) DOI 10.1007/s10557-011-6309-5)). Cardiovascular Drugs and Therapy. 2011 8月;25(4):365-366. doi: 10.1007/s10557-011-6315-7

Ando, Katsuyuki ; Haneda, Masakazu ; Ito, Sadayoshi その他. / Erratum : Design and rationale of japanese evaluation between formula of azelnidipine and amlodipine add on olmesartan to get antialbuminuric effect study (J-FLAG) : Ion of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria (Cardiovascular Drugs and Therapy (2011) 25 (365366) DOI 10.1007/s10557-011-6309-5)). In: Cardiovascular Drugs and Therapy. 2011 ; Vol. 25, No. 4. pp. 365-366.

@article{4ecf708e6ee646cbad3dd25dc4ce8942,

title = "Erratum: Design and rationale of japanese evaluation between formula of azelnidipine and amlodipine add on olmesartan to get antialbuminuric effect study (J-FLAG) : Ion of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria (Cardiovascular Drugs and Therapy (2011) 25 (365366) DOI 10.1007/s10557-011-6309-5))",

author = "Katsuyuki Ando and Masakazu Haneda and Sadayoshi Ito and Naoki Kashihara and Koichi Node and Masaomi Nangaku and Tatsuo Shimosawa and Junji Kishimoto and Toshiro Fujita",

year = "2011",

month = aug,

doi = "10.1007/s10557-011-6315-7",

language = "English",

volume = "25",

pages = "365--366",

journal = "Cardiovascular Drugs and Therapy",

issn = "0920-3206",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - Erratum

T2 - Design and rationale of japanese evaluation between formula of azelnidipine and amlodipine add on olmesartan to get antialbuminuric effect study (J-FLAG) : Ion of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria (Cardiovascular Drugs and Therapy (2011) 25 (365366) DOI 10.1007/s10557-011-6309-5))

AU - Ando, Katsuyuki

AU - Haneda, Masakazu

AU - Ito, Sadayoshi

AU - Kashihara, Naoki

AU - Node, Koichi

AU - Nangaku, Masaomi

AU - Shimosawa, Tatsuo

AU - Kishimoto, Junji

AU - Fujita, Toshiro

PY - 2011/8

Y1 - 2011/8

UR - http://www.scopus.com/inward/record.url?scp=80052280847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052280847&partnerID=8YFLogxK

U2 - 10.1007/s10557-011-6315-7

DO - 10.1007/s10557-011-6315-7

M3 - Comment/debate

AN - SCOPUS:80052280847

SN - 0920-3206

VL - 25

SP - 365

EP - 366

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

IS - 4

ER -